Cargando…

Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei

Burkholderia pseudomallei is the etiological agent of melioidosis. Because of the bacterium’s intrinsic resistance and propensity to establish latent infections, melioidosis therapy is complicated and prolonged. Newer generation β-lactams, specifically ceftazidime, are used for acute phase therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Rholl, Drew A., Papp-Wallace, Krisztina M., Tomaras, Andrew P., Vasil, Michael L., Bonomo, Robert A., Schweizer, Herbert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129521/
https://www.ncbi.nlm.nih.gov/pubmed/21747814
http://dx.doi.org/10.3389/fmicb.2011.00139
_version_ 1782207541813444608
author Rholl, Drew A.
Papp-Wallace, Krisztina M.
Tomaras, Andrew P.
Vasil, Michael L.
Bonomo, Robert A.
Schweizer, Herbert P.
author_facet Rholl, Drew A.
Papp-Wallace, Krisztina M.
Tomaras, Andrew P.
Vasil, Michael L.
Bonomo, Robert A.
Schweizer, Herbert P.
author_sort Rholl, Drew A.
collection PubMed
description Burkholderia pseudomallei is the etiological agent of melioidosis. Because of the bacterium’s intrinsic resistance and propensity to establish latent infections, melioidosis therapy is complicated and prolonged. Newer generation β-lactams, specifically ceftazidime, are used for acute phase therapy, but resistance to this cephalosporin has been observed. The chromosomally encoded penA gene encodes a putative twin arginine translocase (TAT)-secreted β-lactamase, and penA mutations have been implicated in ceftazidime resistance in clinical isolates. However, the role of PenA in resistance has not yet been systematically studied in isogenetic B. pseudomallei mutant backgrounds. We investigated the effects of penA deletion, point mutations, and up-regulation, as well as tat operon deletion and PenA TAT-signal sequence mutations. These experiments were made possible by employing a B. pseudomallei strain that is excluded from Select Agent regulations. Deletion of penA significantly (>4-fold) reduced the susceptibility to six of the nine β-lactams tested and ≥16-fold for ampicillin, amoxicillin, and carbenicillin. Overexpression of penA by single-copy, chromosomal expression of the gene under control of the inducible P(tac) promoter, increased resistance levels for all β-lactams tested 2- to 10-fold. Recreation of the C69Y and P167S PenA amino acid substitutions previously observed in resistant clinical isolates increased resistance to ceftazidime by ≥85- and 5- to 8-fold, respectively. Similarly, a S72F substitution resulted in a 4-fold increase in resistance to amoxicillin and clavulanic acid. Susceptibility assays with PenA TAT-signal sequence and ΔtatABC mutants, as well as Western blot analysis, confirmed that PenA is a TAT secreted enzyme and not periplasmic but associated with the spheroplastic cell fraction. Lastly, we determined that two LysR-family regulators encoded by genes adjacent to penA do not play a role in transcriptional regulation of penA expression.
format Online
Article
Text
id pubmed-3129521
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-31295212011-07-11 Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei Rholl, Drew A. Papp-Wallace, Krisztina M. Tomaras, Andrew P. Vasil, Michael L. Bonomo, Robert A. Schweizer, Herbert P. Front Microbiol Microbiology Burkholderia pseudomallei is the etiological agent of melioidosis. Because of the bacterium’s intrinsic resistance and propensity to establish latent infections, melioidosis therapy is complicated and prolonged. Newer generation β-lactams, specifically ceftazidime, are used for acute phase therapy, but resistance to this cephalosporin has been observed. The chromosomally encoded penA gene encodes a putative twin arginine translocase (TAT)-secreted β-lactamase, and penA mutations have been implicated in ceftazidime resistance in clinical isolates. However, the role of PenA in resistance has not yet been systematically studied in isogenetic B. pseudomallei mutant backgrounds. We investigated the effects of penA deletion, point mutations, and up-regulation, as well as tat operon deletion and PenA TAT-signal sequence mutations. These experiments were made possible by employing a B. pseudomallei strain that is excluded from Select Agent regulations. Deletion of penA significantly (>4-fold) reduced the susceptibility to six of the nine β-lactams tested and ≥16-fold for ampicillin, amoxicillin, and carbenicillin. Overexpression of penA by single-copy, chromosomal expression of the gene under control of the inducible P(tac) promoter, increased resistance levels for all β-lactams tested 2- to 10-fold. Recreation of the C69Y and P167S PenA amino acid substitutions previously observed in resistant clinical isolates increased resistance to ceftazidime by ≥85- and 5- to 8-fold, respectively. Similarly, a S72F substitution resulted in a 4-fold increase in resistance to amoxicillin and clavulanic acid. Susceptibility assays with PenA TAT-signal sequence and ΔtatABC mutants, as well as Western blot analysis, confirmed that PenA is a TAT secreted enzyme and not periplasmic but associated with the spheroplastic cell fraction. Lastly, we determined that two LysR-family regulators encoded by genes adjacent to penA do not play a role in transcriptional regulation of penA expression. Frontiers Research Foundation 2011-07-01 /pmc/articles/PMC3129521/ /pubmed/21747814 http://dx.doi.org/10.3389/fmicb.2011.00139 Text en Copyright © 2011 Rholl, Papp-Wallace, Tomaras, Vasil, Bonomo and Schweizer. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
spellingShingle Microbiology
Rholl, Drew A.
Papp-Wallace, Krisztina M.
Tomaras, Andrew P.
Vasil, Michael L.
Bonomo, Robert A.
Schweizer, Herbert P.
Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title_full Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title_fullStr Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title_full_unstemmed Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title_short Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei
title_sort molecular investigations of pena-mediated β-lactam resistance in burkholderia pseudomallei
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129521/
https://www.ncbi.nlm.nih.gov/pubmed/21747814
http://dx.doi.org/10.3389/fmicb.2011.00139
work_keys_str_mv AT rholldrewa molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei
AT pappwallacekrisztinam molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei
AT tomarasandrewp molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei
AT vasilmichaell molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei
AT bonomoroberta molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei
AT schweizerherbertp molecularinvestigationsofpenamediatedblactamresistanceinburkholderiapseudomallei